GlassScriptPhysician profile
Assel Aldajeh
NPI 1457973745
$679.88
in general payments reported to CMS, 2019-2025
14 companies · $426 in 2025
The $426 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $254 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $141.56 | 2025 | Zoryve |
| Sanofi Pasteur INC. | $90.48 | 2024-2025 | |
| Glaxosmithkline, LLC. | $87.15 | 2024-2025 | Bexsero, Pediarix, Rotarix |
| Cranial Technologies, INC | $59.03 | 2024-2025 | Doc Band |
| Pfizer INC. | $46.96 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $46.28 | 2024-2025 | Vaxelis, Rotateq, Enflonsia |
| Sobi, INC | $33.82 | 2024 | |
| Collegium Pharmaceutical, INC. | $32.37 | 2025 | Jornay Pm |
| Tris Pharma INC | $30.39 | 2024 | Dyanavel Xr |
| Neos Therapeutics, LP | $29.61 | 2024-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $24.18 | 2025 | Elaprase |
| Azurity Pharmaceuticals, INC. | $21.54 | 2025 | Alvesco |
| Tempus Ai, INC | $21.01 | 2024 | Tempus Pixel |
| Cumberland Pharmaceuticals, INC. | $15.50 | 2024 | Kristalose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Assel Aldajeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.